STAD + RT Arm(n = 45) | Endpoints | Covariate | Comparison | HR* | 95% CI | p-value** |
---|---|---|---|---|---|---|
 | Overall Survival | VEGF | 0-1 vs. | RL | (0.734, 2.745) | 0.299 |
2-3 | 1.419 | |||||
Age | < 71 vs. | RL | (0.608, 2.910) | 0.475 | ||
≥ 71 | 1.330 | |||||
Combined Gleason Score | 2-6 vs. | RL | (0.393, 2.581) | 0.988 | ||
7-10 | 1.007 | |||||
Clinical Stage | T2 vs. | RL | (0.213, 1.196) | 0.120 | ||
T3 | 0.505 | |||||
Distant Metastasis | VEGF | 0-1 vs. | RL | (0.264, 1.326) | 0.200 | |
2-3 | 0.592 | |||||
Age | < 71 vs. | RL | (0.813, 6.614) | 0.120 | ||
≥71 | 2.318 | |||||
Combined Gleason Score | 2-6 vs. | RL | (1.622,61.105) | 0.013†| ||
7-10 | 9.957 | |||||
Clinical Stage | T2 vs. | RL | (0.376, 3.580) | 0.800 | ||
T3 | 1.160 | |||||
Local Progression | VEGF | 0-1vs. | RL | (0.321, 2.064) | 0.660 | |
2-3 | 0.814 | |||||
Age | < 71 vs. | RL | ( 0.288, 3.515) | 0.990 | ||
≥71 | 1.006 | |||||
Combined Gleason Score | 2-6 vs. | RL | (0.420, 9.427) | 0.390 | ||
7-10 | 1.990 | |||||
Clinical Stage | T2 vs. | RL | (0.146, 1.755) | 0.280 | ||
T3 | 0.506 | |||||
Disease-free Survival | VEGF | 0-1vs. | RL | (0.273, 0.995) | 0.048†| |
2-3 | 0.521 | |||||
Age | < 71 vs. | RL | (0.807, 3.601) | 0.162 | ||
≥ 71 | 1.705 | |||||
Combined Gleason Score | 2-6 vs. | RL | (0.792, 4.567) | 0.150 | ||
7-10 | 1.902 | |||||
Clinical Stage | T2 vs. | RL | (0.403, 2.054) | 0.052 | ||
T3 | 0.910 | |||||
Biochemical Failure | VEGF | 0-1vs. | RL | (0.251, 1.170) | 0.120 | |
2-3 | 0.542 | |||||
Age | < 71 vs. | RL | (0.805, 3.834) | 0.160 | ||
≥ 71 | 1.757 | |||||
Combined Gleason Score | 2-6 vs. | RL | (0.783, 14.343) | 0.100 | ||
7-10 | 3.352 | |||||
Clinical Stage | T2 vs. | RL | (0.425, 3.151) | 0.780 | ||
T3 | 1.157 | |||||
RT Alone Arm(n = 58) | Endpoints | Covariate | Comparison | HR* | 95% CI | p-value** |
Overall Survival | VEGF | 0-1 vs. | RL | (0.622, 2.028) | 0.699 | |
2-3 | 1.123 | |||||
Age | < 71 vs. | RL | (0.890, 2.800) | 0.118 | ||
≥ 71 | 1.579 | |||||
Combined Gleason Score | 2-6 vs. | RL | (0.839, 2.566) | 0.178 | ||
7-10 | 1.468 | |||||
Clinical Stage | T2 vs. | RL | (0.760, 2.917) | 0.246 | ||
T3 | 1.489 | |||||
Distant Metastasis | VEGF | 0-1 vs. | RL | (0.777, 3.319) | 0.200 | |
2-3 | 1.606 | |||||
Age | < 71 vs. | RL | (0.422, 1.706) | 0.640 | ||
≥71 | 0.848 | |||||
Combined Gleason Score | 2-6 vs. | RL | (0.992, 3.825) | 0.053 | ||
7-10 | 1.947 | |||||
Clinical Stage | T2 vs. | RL | (0.357, 1.789) | 0.590 | ||
T3 | 0.800 | |||||
Local Progression | VEGF | 0-1vs. | RL | (0.670, 2.669) | 0.410 | |
2-3 | 1.337 | |||||
Age | < 71 vs. | RL | (0.391, 1.643) | 0.540 | ||
≥71 | 0.801 | |||||
Combined Gleason Score | 2-6 vs. | RL | (0.259, 1.067) | 0.075 | ||
7-10 | 0.525 | |||||
Clinical Stage | T2 vs. | RL | (0.415, 1.971) | 0.800 | ||
T3 | 0.905 | |||||
Disease-free Survival | VEGF | 0-1vs. | RL | (0.779, 2.371) | 0.279 | |
2-3 | 1.359 | |||||
Age | < 71 vs. | RL | (0.305, 0.979) | 0.042†| ||
≥ 71 | 0.547 | |||||
Combined Gleason Score | 2-6 vs. | RL | (1.021, 3.537) | 0.043†| ||
7-10 | 1.900 | |||||
Clinical Stage | T2 vs. | RL | (0.473, 1.913) | 0.889 | ||
T3 | 0.952 | |||||
Biochemical Failure | VEGF | 0-1vs. | RL | (0.815, 2.562) | 0.210 | |
2-3 | 1.446 | |||||
Age | < 71 vs. | RL | (0.315, 1.104) | 0.056 | ||
≥ 71 | 0.565 | |||||
Combined Gleason Score | 2-6 vs. | RL | (0.655, 2.356) | 0.510 | ||
7-10 | 1.242 | |||||
Clinical Stage | T2 vs. | RL | (0.474, 2.459) | 0.850 | ||
 |  |  | T3 | 1.080 |  |  |